Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI (IMAGE)

Dana-Farber Cancer Institute

Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI

Caption

Dana-Farber Cancer Institute, Boston, MA.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly courtesy Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.